Palisade Bio Inc (PALI)

$2.23 +0.34 (17.99%)
Market Cap 328.07M
Revenue (ttm) 0.00
Net Income (ttm) -16.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 11,131,200
Avg Vol 3,670,216
Day's Range N/A - N/A
Shares Out 173.58M
Stochastic %K 63%
Beta 1.52
Analysts Strong Sell
Price Target $10.00

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pha...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4900
Address:
4600 South Syracuse Street, Suite 900, Denver, United States
Machiaveltrade
Machiaveltrade Jun. 29 at 8:51 PM
$PALI and $ABVX my two precious….never sell 😁
0 · Reply
Machiaveltrade
Machiaveltrade Jun. 29 at 8:26 PM
$PALI major position here and no sell …LT hold
0 · Reply
balzofsteel
balzofsteel Jun. 29 at 6:19 PM
$PALI I’m balls deep in PALI. And I’m not ready to dump. More like I’m ready to hump . See y’all at $20
1 · Reply
StocktwitsNews
StocktwitsNews Jun. 29 at 5:49 PM
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? $PALI https://stocktwits.com/news/equity/markets/palisade-bio-pali-stock-rally-fda-ind-approval-ulcerative-colitis-drug/cZ190XcR7LW
0 · Reply
Muslimmah
Muslimmah Jun. 29 at 5:25 PM
$PALI FDA approval.
0 · Reply
notreload_ai
notreload_ai Jun. 29 at 4:49 PM
The FDA has cleared $PALI investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026. https://notreload.xyz/xy/palisade-bio-jumps-after-fda-clears-pali-2108-phase-2/
0 · Reply
ronburgandy75
ronburgandy75 Jun. 29 at 2:04 PM
$PALI i guessback to baseline $2.00
0 · Reply
ronburgandy75
ronburgandy75 Jun. 29 at 1:59 PM
$PALI should be above $3.X
0 · Reply
ronburgandy75
ronburgandy75 Jun. 29 at 1:58 PM
$PALI can this really climb on good news?
0 · Reply
Muslimmah
Muslimmah Jun. 29 at 1:40 PM
$PALI let’s go, finally after a very very long wait.
0 · Reply
Latest News on PALI
Palisade Bio receives FDA clearance to start ulcerative colitis study

2026-06-29T13:10:09.000Z - 11 hours ago

Palisade Bio receives FDA clearance to start ulcerative colitis study

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Jun 29, 2026, 8:30 AM EDT - 11 hours ago

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Jun 11, 2026, 8:45 AM EDT - 18 days ago

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium

Jun 9, 2026, 8:45 AM EDT - 20 days ago

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium

Palisade Bio Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 3:45 PM EDT - 25 days ago

Palisade Bio Transcript: Jefferies Global Healthcare Conference 2026

Palisade Bio Slides: Corporate presentation

Jun 4, 2026, 7:00 AM EDT - 25 days ago

Palisade Bio Slides: Corporate presentation

Palisade Bio to Participate in the Jefferies Global Healthcare Conference

May 27, 2026, 9:00 AM EDT - 4 weeks ago

Palisade Bio to Participate in the Jefferies Global Healthcare Conference

Palisade Bio Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 6 weeks ago

Palisade Bio Slides: Corporate presentation

Palisade Bio files $300M mixed securities shelf

2026-05-12T22:21:57.000Z - 6 weeks ago

Palisade Bio files $300M mixed securities shelf

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

May 12, 2026, 4:15 PM EDT - 6 weeks ago

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

Palisade Bio Registration statement: Registration filing

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Palisade Bio Registration statement: Registration filing

Palisade Bio Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Palisade Bio Quarterly report: Q1 2026

Palisade Bio Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Palisade Bio Earnings release: Q1 2026

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

May 5, 2026, 8:30 AM EDT - 7 weeks ago

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Proxy statement: Proxy filing

Palisade Bio Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Proxy statement: Proxy filing

Palisade Bio Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Proxy statement: Proxy filing

Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 2:15 PM EDT - 2 months ago

Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

Apr 16, 2026, 8:50 AM EDT - 2 months ago

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

Palisade Bio initiated with an Outperform at Wolfe Research

2026-04-08T20:43:15.000Z - 2 months ago

Palisade Bio initiated with an Outperform at Wolfe Research

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Apr 8, 2026, 9:00 AM EDT - 2 months ago

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Palisade Bio Slides: Corporate presentation

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Palisade Bio Slides: Corporate presentation

Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street

2026-03-31T20:38:39.000Z - 3 months ago

Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street

Palisade Bio Transcript: Study result

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Palisade Bio Transcript: Study result

Palisade Bio Press release: Study result

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Palisade Bio Press release: Study result

Palisade Bio Slides: Study result

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Palisade Bio Slides: Study result

Palisade Bio announces topline data from PALI-2108 trial

2026-03-30T20:19:16.000Z - 3 months ago

Palisade Bio announces topline data from PALI-2108 trial

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

Mar 30, 2026, 4:01 PM EDT - 3 months ago

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

Palisade Bio initiated with a Buy at H.C. Wainwright

2026-03-26T10:11:33.000Z - 3 months ago

Palisade Bio initiated with a Buy at H.C. Wainwright

Palisade Bio Annual report: Q4 2025

Mar 20, 2026, 7:00 AM EDT - 3 months ago

Palisade Bio Annual report: Q4 2025

Palisade Bio Slides: Corporate presentation

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Palisade Bio Slides: Corporate presentation

Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:10 PM EST - 4 months ago

Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Mar 2, 2026, 9:00 AM EST - 4 months ago

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Palisade Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 12:40 PM EST - 4 months ago

Palisade Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Palisade Bio initiated with a Buy at Stifel

2026-02-24T21:52:07.000Z - 4 months ago

Palisade Bio initiated with a Buy at Stifel

Palisade Bio announces presentation of new data for PALI-2108

2026-02-23T13:47:18.000Z - 4 months ago

Palisade Bio announces presentation of new data for PALI-2108

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Feb 23, 2026, 8:40 AM EST - 4 months ago

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Palisade Bio appoints Verstockt to its Clinical Advisory Board

2026-02-17T14:05:21.000Z - 4 months ago

Palisade Bio appoints Verstockt to its Clinical Advisory Board

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Feb 17, 2026, 8:45 AM EST - 4 months ago

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 9, 2026, 9:00 AM EST - 5 months ago

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 5, 2026, 8:45 AM EST - 5 months ago

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board

2026-01-29T13:50:44.000Z - 5 months ago

Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Jan 29, 2026, 8:45 AM EST - 5 months ago

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Jan 16, 2026, 8:30 AM EST - 5 months ago

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Palisade Bio initiated with a Buy at B. Riley

2026-01-09T10:35:21.000Z - 6 months ago

Palisade Bio initiated with a Buy at B. Riley

Palisade Bio announces equity investment from Crohn’s & Colitis Foundation

2026-01-07T13:25:34.000Z - 6 months ago

Palisade Bio announces equity investment from Crohn’s & Colitis Foundation

Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

Jan 7, 2026, 8:15 AM EST - 6 months ago

Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

Palisade Bio granted Japanese patent covering PALI-2108

2025-12-30T13:45:55.000Z - 6 months ago

Palisade Bio granted Japanese patent covering PALI-2108

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Dec 30, 2025, 8:35 AM EST - 6 months ago

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Palisade Bio initiated with a Buy at Clear Street

2025-12-29T21:10:18.000Z - 6 months ago

Palisade Bio initiated with a Buy at Clear Street

Palisade Bio initiated with an Overweight at Piper Sandler

2025-12-29T09:30:14.000Z - 6 months ago

Palisade Bio initiated with an Overweight at Piper Sandler

Palisade Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 10:30 AM EST - 7 months ago

Palisade Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Palisade Bio appoints James Izanec as VP, clinical development

2025-12-02T13:55:38.000Z - 7 months ago

Palisade Bio appoints James Izanec as VP, clinical development

BMY

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Dec 2, 2025, 8:45 AM EST - 7 months ago

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:45 AM EST - 7 months ago

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Palisade Bio price target raised to $8 from $2 at Maxim

2025-11-11T17:45:32.000Z - 8 months ago

Palisade Bio price target raised to $8 from $2 at Maxim

Palisade Bio Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 8 months ago

Palisade Bio Quarterly report: Q3 2025

Palisade Bio Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 8 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio appoints Sharon Skare as global head, clinical operations

2025-10-28T12:50:12.000Z - 8 months ago

Palisade Bio appoints Sharon Skare as global head, clinical operations

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Oct 28, 2025, 8:45 AM EDT - 8 months ago

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Palisade Bio Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Oct 20, 2025, 8:45 AM EDT - 9 months ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Proxy statement: Proxy Filing

Oct 17, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio Slides: Corporate Presentation

Oct 15, 2025, 6:00 PM EDT - 9 months ago

Palisade Bio Slides: Corporate Presentation

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Oct 13, 2025, 8:45 AM EDT - 9 months ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Oct 9, 2025, 5:00 PM EDT - 9 months ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Palisade Bio Proxy statement: Proxy Filing

Oct 7, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Oct 2, 2025, 4:05 PM EDT - 9 months ago

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Oct 1, 2025, 9:20 AM EDT - 9 months ago

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Palisade Bio Registration statement: Registration Filing

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Registration statement: Registration Filing

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Sep 26, 2025, 4:05 PM EDT - 9 months ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Sep 17, 2025, 9:00 AM EDT - 10 months ago

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio Proxy statement: Proxy Filing

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio Proxy statement: Proxy Filing

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Sep 5, 2025, 8:45 AM EDT - 10 months ago

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Proxy statement: Proxy Filing

Sep 5, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 25, 2025, 9:00 AM EDT - 11 months ago

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Palisade Bio Proxy statement: Proxy Filing

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio Registration statement: Registration Filing

Aug 15, 2025, 8:00 AM EDT - 11 months ago

Palisade Bio Registration statement: Registration Filing

Palisade Bio Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Palisade Bio Quarterly report: Q2 2025

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Aug 7, 2025, 9:15 AM EDT - 11 months ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Palisade Bio Proxy statement: Proxy Filing

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Palisade Bio Proxy statement: Proxy Filing

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 31, 2025, 8:45 AM EDT - 11 months ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 23, 2025, 8:00 PM EDT - 1 year ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 1 year ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Jul 9, 2025, 8:45 AM EDT - 1 year ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 27, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

Palisade Bio Registration statement: Registration Filing

May 27, 2025, 8:00 AM EDT - 1 year ago

Palisade Bio Registration statement: Registration Filing

Palisade Bio Quarterly report: Q1 2025

May 11, 2025, 6:00 PM EDT - 1 year ago

Palisade Bio Quarterly report: Q1 2025

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 6, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

May 1, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Apr 9, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Annual report: Q4 2024

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Palisade Bio Annual report: Q4 2024

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Mar 4, 2025, 8:30 AM EST - 1 year ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 20, 2025, 8:45 AM EST - 1 year ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Palisade Bio Transcript: Virtual Investor "Top 5 for '25"

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio Transcript: Virtual Investor "Top 5 for '25"

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Feb 10, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 29, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 5:20 PM EST - 1 year ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 17, 2024, 8:30 AM EST - 1 year ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 13, 2024, 4:05 PM EST - 1 year ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Machiaveltrade
Machiaveltrade Jun. 29 at 8:51 PM
$PALI and $ABVX my two precious….never sell 😁
0 · Reply
Machiaveltrade
Machiaveltrade Jun. 29 at 8:26 PM
$PALI major position here and no sell …LT hold
0 · Reply
balzofsteel
balzofsteel Jun. 29 at 6:19 PM
$PALI I’m balls deep in PALI. And I’m not ready to dump. More like I’m ready to hump . See y’all at $20
1 · Reply
StocktwitsNews
StocktwitsNews Jun. 29 at 5:49 PM
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? $PALI https://stocktwits.com/news/equity/markets/palisade-bio-pali-stock-rally-fda-ind-approval-ulcerative-colitis-drug/cZ190XcR7LW
0 · Reply
Muslimmah
Muslimmah Jun. 29 at 5:25 PM
$PALI FDA approval.
0 · Reply
notreload_ai
notreload_ai Jun. 29 at 4:49 PM
The FDA has cleared $PALI investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026. https://notreload.xyz/xy/palisade-bio-jumps-after-fda-clears-pali-2108-phase-2/
0 · Reply
ronburgandy75
ronburgandy75 Jun. 29 at 2:04 PM
$PALI i guessback to baseline $2.00
0 · Reply
ronburgandy75
ronburgandy75 Jun. 29 at 1:59 PM
$PALI should be above $3.X
0 · Reply
ronburgandy75
ronburgandy75 Jun. 29 at 1:58 PM
$PALI can this really climb on good news?
0 · Reply
Muslimmah
Muslimmah Jun. 29 at 1:40 PM
$PALI let’s go, finally after a very very long wait.
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 29 at 12:31 PM
$PALI Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
0 · Reply
Merlintrader
Merlintrader Jun. 25 at 3:07 PM
$PALI Russell 2026 Biotech Watchlist: $CNTX $IMMX $CBIO and the Small-Cap Health Care Additions to Watch https://www.merlintrader.com/russell-2026-biotech-watchlist/
0 · Reply
Stormy02
Stormy02 Jun. 23 at 4:46 PM
$MWYN $OCGN $PALI Thanks
0 · Reply
Unicorno
Unicorno Jun. 19 at 1:04 PM
$PALI come on let s start this study management!!! i want 2.7$ at the news!!!
0 · Reply
focafoca99
focafoca99 Jun. 11 at 9:53 PM
$PALI just got a board addition, a bigger share count, and shareholder approval for equity plans after its annual meeting.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Jun. 11 at 5:13 PM
$ADIL A new 'the next $ABVX ' has entered the space after $EQ and $PALI Took a tiny position at 3 for lolz, pump or death
1 · Reply
focafoca99
focafoca99 Jun. 9 at 1:07 PM
$PALI presenting at the New York Academy of Sciences symposium on June 9, highlighting its PALI-2108 candidate for fibrostenotic Crohn’s
0 · Reply
Toadvind
Toadvind Jun. 6 at 9:52 PM
$PALI buy under 1.80, sell over 2.30 rinse repeat
0 · Reply
WhiteFang420
WhiteFang420 Jun. 2 at 3:49 PM
$PALI I expect to see this @ 1.80 minimum, prolly lower.
1 · Reply
masonat
masonat Jun. 1 at 9:49 PM
$PALI Okay I wasn't going to complain as it followed ABVX up but it makes no sense for it to follow it down either 🤣
0 · Reply
dl42
dl42 Jun. 1 at 9:37 PM
$PALI wow up to 2.50 and down to this. It sounds like a big misunderstanding around potential malignancies is ABVX data.
1 · Reply
Pdior77
Pdior77 Jun. 1 at 9:00 PM
$PALI what the fuck
0 · Reply